The development of new treatments in MS has exploded. Currently there are at least 15 disease modifying agents available with more anticipated to be approved in the next few years….
Read More
This week, the results from a clinical trial of 250 participants with progressive MS were released and showed that ibudilast on had a significant impact in slowing down brain volume…
There’s a fundamental difference in opinion in modern MS treatment. On one hand, we have a treatment strategy defined by what amounts to a “wait and see” approach. In this…
This past month, the MSYPN met with RMMSC Board Chair, Del Arnold, and Board Member, Erica Tarpey. Del and Erica discussed their careers, what led them to the RMMSC board, and…
Medical appointments tend to be too short to address all our concerns and care does not always feel patient-centered. In an effort to reme-dy these common experiences and give patients…
One of the most difficult decisions for someone who’s been living with MS for a long time is whether or not to discontinue their treatment with disease modifying therapies (DMTs)….
As we develop treatment strategies that rely on early diagnosis, it’s more important than ever that we identify MS as quickly as possible — and that means watching for common…
This issue of InforMS describes the serious efforts of expert physicians to identify the best strategies to treat people with multiple sclerosis. Unfortunately, however, there is another critical decision maker…
An Interview with Dr. Roger Enoka with the Neurophysiology of Movement Laboratory at University of Colorado Boulder campus Dr. Roger Enoka, a professor at the University of Colorado Boulder, has…
Quite a bit’s going on in the world of disease modifying therapies (DMTs), and we’ve prepared a brief update for you. Read on for more about Gilenya’s FDA approval for…